Novartis data at AAN reinforces commitment to address high unmet medical need and to provide a treatment at every stage of multiple sclerosis
13 March 2013 | By Novartis
New data will be presented...
List view / Grid view
13 March 2013 | By Novartis
New data will be presented...
1 March 2013 | By Novartis
Novartis announced that the European Commission has approved llaris (canakinumab, ACZ885)...
28 February 2013 | By Novartis
Novartis today announced that it has launched an effort to eliminate rheumatic heart disease in Zambia in collaboration with the Lusaka...
24 February 2013 | By Novartis
Late-breaking results from ASTERIA II...
15 February 2013 | By Novartis
The FDA has approved Zortress®...
23 January 2013 | By Novartis
Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia...
22 January 2013 | By Novartis
Bexsero®, first vaccine to prevent the leading cause of life-threatening meningitis across Europe...
18 January 2013 | By Novartis
"Novartis welcomes the decision by the CHMP in support of the approval of Ilaris in the EU"
18 January 2013 | By Novartis
Jetrea(TM) would become the first drug to treat sight-threatening vitreomacular traction and macular hole...
17 January 2013 | By Novartis
"The challenges in delivering healthcare in developing countries are considerable..."
14 January 2013 | By Novartis
Findings from a pivotal Phase III clinical trial...
11 January 2013 | By Novartis
Data published today...
21 December 2012 | By Novartis
The EC has approved Exjade®...
15 December 2012 | By Novartis
The US FDA has approved Signifor®...
11 December 2012 | By Novartis
Novartis announced long-term follow-up data...